Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

40
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
40
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

31
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
31
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

27
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
27
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

39
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
39
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.2K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.2K
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices01:28

Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices

30
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
30

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiscale Dissolution Simulation of Particles from a Tablet in Dissolution Apparatus by Coupling Discrete Element with Lattice Boltzmann Methods.

Pharmaceutical research·2026
Same author

Evaluation of a Novel Flexible Cage System for C5-C6 Fixation: A Finite Element Study Against Conventional ACDF Implants.

Bioengineering (Basel, Switzerland)·2026
Same author

Editorial: Integrated diagnostics and biomarker discovery in endocrinology and biomedical sciences, volume II.

Frontiers in endocrinology·2025
Same author

Recent advances in polymer-based drug delivery systems for atopic dermatitis: enhancing therapeutic efficacy and outcomes.

Materials today. Bio·2025
Same author

Challenges and innovations in long-acting injectable formulations: can formulation design space be rationalized?

The Journal of pharmacy and pharmacology·2025
Same author

Long-Acting injectable buprenorphine PLGA microparticle formulation.

International journal of pharmaceutics·2025
Same journal

Loss of internal structural order induced by freezing and Lyophilization correlates with reduced in vitro activity of mRNA lipid nanoparticles.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Tacrolimus nanocrystal-loaded glycyrrhizic acid hydrogel for the treatment of corneal alkali burn.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Bio-recruiting hydrogel targeting mitochondrial homeostasis under neutrophil extracellular traps for diabetic wound repair.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Cubosomes with pH-triggered cubic phase transition enable cytosolic mRNA delivery for acute respiratory distress syndrome therapy.

Journal of controlled release : official journal of the Controlled Release Society·2026
Same journal

Integrating PD-L1-targeted radioligand with protein degradation for precision tumor theranostics.

Journal of controlled release : official journal of the Controlled Release Society·2026
See all related articles

Related Experiment Video

Updated: Feb 19, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K

Compacted solid implant formulations for long-term buprenorphine delivery.

Andrew Otte1, Kinam Park1

  • 1Purdue University, Weldon School of Biomedical Engineering, West Lafayette, IN 47907, USA.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|February 17, 2026
PubMed
Summary
This summary is machine-generated.

New biodegradable implants offer sustained buprenorphine release for over three months, potentially improving treatment adherence and outcomes for opioid use disorder (OUD). This advancement in long-acting formulations addresses a critical need in OUD management.

Keywords:
BuprenorphineCompacted rod formulationLong-acting injectablesOpioid use disorderPLGA rods

More Related Videos

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

898
Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation
08:56

Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation

Published on: August 1, 2010

17.9K

Related Experiment Videos

Last Updated: Feb 19, 2026

Intravascular Delivery of Biologics to the Rat Kidney
07:29

Intravascular Delivery of Biologics to the Rat Kidney

Published on: September 1, 2016

8.2K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

898
Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation
08:56

Fate Mapping of Human Embryonic Stem Cells by Teratoma Formation

Published on: August 1, 2010

17.9K

Area of Science:

  • Pharmacology
  • Materials Science
  • Drug Delivery Systems

Background:

  • Opioid use disorder (OUD) is a significant public health issue in the US.
  • Medication-assisted treatment with buprenorphine is a key management strategy.
  • Existing long-acting buprenorphine products offer release for 1 week or 1 month.

Purpose of the Study:

  • To develop novel biodegradable poly(lactide-co-glycolide) (PLGA) rod formulations for sustained buprenorphine release.
  • To achieve drug release for a duration of three months or longer.
  • To minimize initial burst release common in PLGA systems.

Main Methods:

  • Buprenorphine free base and PLGA were thermally compacted into solid rods using a plastometer.
  • Manufacturing involved temperatures of 165-180°C and compression loads of 4-16 kg.
  • In vivo pharmacokinetic studies were conducted in rat and dog models.

Main Results:

  • Developed PLGA rod implants containing 70% w/w buprenorphine.
  • Minimized initial burst release through optimized compaction, reducing pore formation.
  • Demonstrated sustained plasma buprenorphine concentrations exceeding three months in animal models.

Conclusions:

  • Novel biodegradable PLGA rods provide sustained buprenorphine release for ≥3 months.
  • These long-acting implants represent a promising advancement for OUD treatment.
  • Potential to enhance patient adherence and improve clinical outcomes in OUD management.